Quah, Hong Sheng http://orcid.org/0000-0001-8430-8528
Cao, Elaine Yiqun
Suteja, Lisda
Li, Constance H.
Leong, Hui Sun
Chong, Fui Teen
Gupta, Shilpi
Arcinas, Camille http://orcid.org/0000-0001-5374-9232
Ouyang, John F. http://orcid.org/0000-0002-1239-1577
Ang, Vivian
Celhar, Teja http://orcid.org/0000-0003-1384-0941
Zhao, Yunqian
Tay, Hui Chen
Chan, Jerry
Takahashi, Takeshi
Tan, Daniel S. W. http://orcid.org/0000-0002-6514-6786
Biswas, Subhra K.
Rackham, Owen J. L. http://orcid.org/0000-0002-4390-0872
Iyer, N. Gopalakrishna http://orcid.org/0000-0002-8812-6219
Funding for this research was provided by:
Khoo Postdoctoral Fellowship Award
Core funding by Singapore Immunology Network
MOH | National Medical Research Council (NMRC/CSA/001/2016, MOH-000325-00)
Peter Fu Head and Neck Cancer Program (under the Oncology Academic Clinical Program, National Cancer Centre Singapore) to NGI
Article History
Received: 14 October 2021
Accepted: 15 March 2023
First Online: 27 March 2023
Competing interests
: NGI has/had a consulting or advisory role in PairX Therapeutics and Invitrocue PLC, and received honoraria from Kalbe Biotech and Agilent, all of which are outside this submitted work. DSWT received honoraria from Bristol-Myers Squibb, Takeda Pharmaceuticals, Novartis, Roche, and Pfizer; and has consulting or advisory role in Novartis, Merck, Loxo Oncology, AstraZeneca, Roche, and Pfizer. DSWT also received research funding from Novartis (Inst), GlaxoSmithKline (Inst), and AstraZeneca (Inst), outside this submitted work. None of the remaining authors have any other conflicts to report.